您当前所在的位置:首页 > 产品中心 > 产品详细信息
78439-06-2 分子结构
点击图片或这里关闭

1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium

ChemBase编号:321
分子式:C22H22N6O7S2
平均质量:546.57608
单一同位素质量:546.09913907
SMILES和InChIs

SMILES:
S1[C@H]2N(C(=O)[C@H]2NC(=O)/C(=N\OC(C)(C)C(=O)O)/c2nc(sc2)N)C(=C(C1)C[n+]1ccccc1)C(=O)[O-]
Canonical SMILES:
O=C1[C@@H](NC(=O)/C(=N\OC(C(=O)O)(C)C)/c2csc(n2)N)[C@@H]2N1C(=C(CS2)C[n+]1ccccc1)C(=O)[O-]
InChI:
InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1
InChIKey:
ORFOPKXBNMVMKC-DWVKKRMSSA-N

引用这个纪录

CBID:321 http://www.chembase.cn/molecule-321.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium
IUPAC传统名
fortum
ceftazidime
商标名
Ceftazidima [INN-Spanish]
Ceftazidime Sodium In Plastic Container
Ceftazidime pentahydrate
Ceftazidimum [INN-Latin]
Ceptaz
Fortaz
Fortaz In Plastic Container
Pentacef
Tazicef
Tazidime
Tazidime In Plastic Container
别名
Ceftazidime
1-[[(6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium Inner Salt Pentahydrate
Biotum
Ceftacidin
Fortam
Fortaz
Fortum
GR 20263
Modacin
Tazicef
Tazidime
Ceftazidime Pentahydrate(Contain 1 equivalent of Na2CO3 as stabilizer)
CAS号
78439-06-2
PubChem SID
160963784
46506143
PubChem CID
5481173

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
TRC
C244100 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 2.7689743  质子受体 10 
质子供体 LogD (pH = 5.5) -5.4758763 
LogD (pH = 7.4) -6.9236097  Log P -4.5463347 
摩尔折射率 143.8809 cm3 极化性 50.377937 Å3
极化表面积 191.22 Å2 可自由旋转的化学键
里宾斯基五规则 false 
Log P -1.21  LOG S -5.02 
溶解度 5.73e-03 g/l 

分子性质

分子性质

理化性质 安全信息 产品相关信息 生物活性(PubChem)
溶解度
396 mg/L expand 查看数据来源
DMSO expand 查看数据来源
Methanol expand 查看数据来源
water expand 查看数据来源
外观
White Solid expand 查看数据来源
熔点
>150°C (dec.) expand 查看数据来源
疏水性(logP)
-1.60 expand 查看数据来源
保存条件
-20°C Freezer expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
质检报告
下载链接 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank TRC TRC
DrugBank -  DB00438 external link
Item Information
Drug Groups approved
Description Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients. [PubChem]
Indication For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Pharmacology Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins.
Toxicity Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
Affected Organisms
Enteric bacteria and other eubacteria
Absorption The absorption of ceftazidime is directly proportional to the size of the dose.
Half Life Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.
Protein Binding < 10%
Elimination The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.
Clearance * 115 mL/min
External Links
Wikipedia
RxList
Drugs.com
Toronto Research Chemicals -  C244100 external link
Third generation cephalosporin antibiotic. Antibacterial.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Brodie, A., et al.: Antimicrob. Agents Chemother., 17, 876 (1980)
  • Richards, D.M., et al.: Drugs, 29, 105 (1980)
  • Abounassif, M.A., et al.: Anal. Profiles Drug Subs., 19, 95 (1980)
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle